Hepatocellular Carcinoma Market Size, Share, By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiotherapy, and Others), By Drug Class (Tyrosine Kinase Inhibitors (TKIs), Multikinase Inhibitors, Monoclonal Antibodies, Immunomodulators, and Others), By Distribution Channel ((Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and By Region - Trends, Analysis and Forecast till 2034

• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Bayer AG
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Pfizer Inc.
• Eisai Co., Ltd.
• AstraZeneca plc
• Johnson & Johnson
• Exelixis, Inc.
• Ipsen Pharma
• Amgen Inc.
• Gilead Sciences, Inc.
• Sanofi S.A.

Recent News:

• Researchers revealed a potential biomarker for the early diagnosis of hepatocellular cancer in July 2024. The biomarker, which comes from a blood-based test, may reliably identify early-stage HCC in high-risk individuals, especially those who have chronic liver conditions, including cirrhosis and hepatitis. Since HCC is frequently discovered late in the disease process, when treatment options are most limited, this study has important implications for improving early diagnosis. This discovery is anticipated to enhance screening initiatives and encourage early interventions.
• Lenvatinib, a novel oral tyrosine kinase inhibitor (TKI), was introduced in Europe in May 2024 as a treatment for incurable hepatocellular cancer. For individuals who are not candidates for surgery, this medication provides a new option because it has demonstrated more success in clinical trials. The capacity of ponatinib to increase progression-free survival and enhance quality of life was the primary factor in its approval. Its introduction fills a gap in the European market and reflects the growing momentum in targeted treatments for HCC.
• The U.S. Food and Drug Administration (FDA) approved a novel combination medication consisting of atezolizumab and bevacizumab for treating advanced hepatocellular carcinoma in March 2024. This combination targets cancer cells more efficiently by utilizing immunotherapy and anti-angiogenesis methods. The approval was granted based on encouraging outcomes from Phase III clinical research that showed higher survival rates and slower disease progression than earlier conventional medicines. This development marks a significant advancement for first-line therapy choices for advanced HCC.